Pharmacological aspects of the treatment of conduct disorder in children and adolescents

CNS Drugs

Volumn 20, Issue 7, 2006, Pages 549-565

  Tcheremissine, Oleg V ^a   Lieving, Lori M ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; CARBAMAZEPINE; CITALOPRAM; CLONIDINE; DEXAMPHETAMINE; FLUOXETINE; HALOPERIDOL; LITHIUM; METHYLPHENIDATE; MOLINDONE; OLANZAPINE; PLACEBO; REBOXETINE; RISPERIDONE; THIORIDAZINE; TRAZODONE; VALPROATE SEMISODIUM; VALPROIC ACID;

AGE DISTRIBUTION; AGGRESSION; ANTISOCIAL BEHAVIOR; CLINICAL TRIAL; CONDUCT DISORDER; DISEASE CLASSIFICATION; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERABILITY; HUMAN; HYPERACTIVITY; IMPULSIVENESS; MOOD DISORDER; PARENT COUNSELING; PREVALENCE; PRIORITY JOURNAL; REVIEW; SEDATION; SEX DIFFERENCE; SIDE EFFECT;

ADOLESCENT; ADRENERGIC AGONISTS; ANTICONVULSANTS; ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; CHILD; CONDUCT DISORDER; FEMALE; HUMANS; MALE; SEX FACTORS;

EID: 33745625855     PISSN: 11727047     EISSN: 11727047     Source Type: Journal    
DOI: 10.2165/00023210-200620070-00002     Document Type: Review

References (118)

1. Blumstein A. Youth violence, guns, and the illicit-drug industry. J Crim Law Criminol 1995; 86 (1): 10-36
2. Rosenberg ML, O'Carroll PW, Powell KE. Let's be clear: violence is a public health problem. JAMA 1992; 267 (22): 3071-2
3. Centers for Disease Control and Prevention. Years of potential life lost before 65: United States, 1980-1991. Morb Mortal Wkly Rep 1993; 42 (130): 251-3
4. Kazdin A. Treatment for aggressive and antisocial children. Child Adolesc Psychiatr Clin N Am 2000; 9: 841-58
5. Clark DB, Jacob RG, Mezzich A. Anxiety and conduct disorder in early onset alcoholism. Ann N Y Acad Sci 1994; 708: 181-6
6. Moss HB, Lynch KG. Comorbid disruptive behavior disorder symptoms and their relationship to adolescent alcohol use disorders. Drug Alcohol Depend 2001; 64: 75-83
7. Myers MG, Brown SA, Mott MA. Preadolescent conduct disorder behaviors predict relapse and progression of addiction for adolescent alcohol and drug abusers. Alcohol Clin Exp Res 1995; 19: 1528-36
8. Foster EM, Jones DE. The high costs of aggression: public expenditures resulting from conduct disorder. Am J Public Health 2005; 95 (10): 1767-72
9. Findling RL. Paediatric psychopharmacology: closing the gap between science and practice. Expert Opin Pharmacother 2001; 2 (4): 523-5
10. American Psychiatric Association. 4th ed., text rev. Diagnostic and statistical manual of mental disorders. Washington, DC: American Psychiatric Association, 2000
11. Robins LN, McEvoy LT. Conduct problems as predictors of substance abuse. In: Robins LN, Rutter M, editors. Straight and deviant pathways from childhood to adulthood. New York: Cambridge University Press, 1990: 182-204
12. Loeber R, Hay D. Key in the development of aggression and violence from childhood to early adulthood. Annu Rev Psychol 1997; 48: 371-410
13. Angold A, Costello EJ, Erkani A. Comorbidity. J Child Psychol Psychiatry 1999; 40 (1): 57-87
14. World Health Organisation. ICD-10: classification of mental and behavioural disorders: clinical description and diagnostic guidelines. Geneva: World Health Organization, 1992
15. Nock MK, Kazdin AE, Hiripi E, et al. Prevalence, subtypes, and correlates of DSM-IV conduct disorder in the National Comorbidity Survey Replication. Psychiatry Med 2006 Jan 26 [Epub ahead of print]
16. Robins LN. Deviant children grown up. Baltimore (MD): Williams and Wilkins, 1966
17. Wade TJ. Delinquency and health among adolescents: multiple outcomes of a similar social and structural process. Int J Law Psychiatry 2001; 24: 447-67
18. Yoshikawa H. Long-term effects of early childhood programs on social outcomes and delinquency. Future Child 1995; 5: 51-75
19. Pevalin DJ, Wade TJ, Brannigan A. Precursors, consequences and implications for stability and change in pre-adolescent antisocial behavior. Prev Sci 2003; 4: 123-36
20. Regier DA, Myers JK, Kramer M, et al. The NIMH epidemiologic catchment area program: historical context, major objectives, and study population characteristics. Arch Gen Psychiatry 1984; 41: 934-41
21. Zoccolilo M, Rogers K. Characteristics and outcome of hospitalized adolescent girls with conduct disorder. J Am Acad Child Adolesc Psychiatry 1991; 30: 973-81
22. Eagly AH, Steffen VJ. Gender and aggressive behavior: a meta-analytic review of the social psychological literature. Psychol Bull 1986; 100: 309-30
23. Maccoby EE, Jacklin CN. Sex differences in aggression: a rejoinder and reprise. Child Dev 1980; 51: 964-80
24. Crick NR, Grotpeter JK. Relational aggression, gender, and social-psychological adjustment. Child Dev 1995; 66: 710-22
25. Lagerspetz KMJ, Bjorkqvist K, Peltonen T. Is indirect aggression typical of females? Gender differences in aggressiveness in 11-12 year old children. Aggress Behav 1988; 14: 402-14
26. Hettema JM, Prescott CA, Kendler K. The effects of anxiety, substance use and conduct disorders on risk of major depresin sive disorder. Psychol Med 2003; 33: 1423-32
27. Preskorn S, Baker B. The overlap of DSM-IV syndromes: potential implications for the practice of polypsychopharmacology, psychiatric drug development, and human genome project. J Psychiatr Pract 2002; 8: 170-7
28. Van Praag H. Over the mainstream: diagnostic requirements for biological psychiatric research. Psychiatry Res 1997; 72: 201-12
29. Paris J. Antisocial and borderline personality disorders: two separate diagnoses or two aspects of the same psychopathology? Compr Psychiatry 1997; 38 (4): 237-42
30. Biederman J, Faraone SV, Milberger S, et al. Is childhood oppositional defiant disorder a precursor to adolescent conduct disorder? Findings from a four-year follow-up study of children with ADHD. J Am Acad Child Adolesc Psychiatry 1996; 35: 1193-204
31. Zoccolillo M, Pickles A, Quintan D, et al. The outcome of childhood conduct disorder: implications for defining adult personality disorder and conduct disorder. Psychol Med 1992; 22: 971-86
32. Robins LN. Sturdy childhood predictors of adult antisocial behavior: replication from longitudinal analyses. Psychol Med 1978; 8: 611-22
33. Quay HC, Peterson DR. Revised behavior problem checklist: professional manual. Odessa (FL): Psychological Assessment Resources, Inc., 1993
34. Achenbach TM. Manual for child behaviour checklist and 1991 profile. Burlington (VT): University of Vermont, Department of Psychiatry, 1991
35. Tackett JL, Krueger RF, Sawyer MG, et al. Subfactors of DSM-IV conduct disorder: evidence and connections with syndromes from the child behavior checklist. J Abnorm Child Psychol 2003; 31 (6): 647-54
36. Campbell M, Gonzalez NM, Silva RR. The pharmacologic treatment of conduct disorders and rage outbursts. Psychiatr Clin North Am 1992; 15 (1): 69-85
37. Waddel C, Lipman E, Offord D. Conduct disorder: practice parameters for assessment, treatment, and prevention. Can J Psychiatry 1999; 44 Suppl. 2: 355-405
38. Cadoret RJ, Yates WR, Troughton E, et al. Adoption study demonstrating two genetic pathways to drug abuse. Arch Gen Psychiatry 1995; 52: 42-52
39. Biederman J, Wilens T, Mick E, et al. Is ADHD a risk factor for psychoactive substance use disorders? Findings from a four-year prospective follow-up study. J Am Acad Child Adolesc Psychiatry 1997; 36: 21-9
40. Hundleby JD, Carpenter RA, Ross RA, et al. Adolescent drug use and other behaviors. J Child Psychol Psychiatry 1982; 23: 61-8
41. Donovan JE, Jessor R. Structure of problem behavior in adolescence and young adulthood. J Consult Clin Psychol 1985; 53: 890-904
42. Kingery PM, Pruitt BE, Hurley RS. Violence and illegal drug use among adolescents: evidence from the US National Adolescent Student Health Survey. Int J Addict 1992; 27: 1445-64
43. Centers for Disease Control and Prevention. Youth risk behavior surveillance: United States, 2001. Morb Mortal Wkly Rep 2002: 51: SS-4
44. Aman MG, De Smedt G, Derivan A, et al. Double-blind, placebo-controlled study of risperidone for the treatment of disruptive behaviors in children with subaverage intelligence. Am J Psychiatry 2002; 159: 1337-46
45. Reyes M, Buitelaar J, Toren R, et al. A randomized, double-blind, placebo-controlled study of risperidone maintenance treatment in children and adolescents with disruptive behavior disorders. Am J Psychiatry 2006; 163: 402-10
46. Findling RL, Blumer JL, Kauffman R, et al. Pharmacokinetic effects of aripiprazole in children and adolescents with conduct disorder [poster]. 24th Collegium Internationale Neuro-Psychopharmacologicum Congress; 2004 Jun 20-24; Paris
47. Campbell M, Adams PB, Small AM, et al. Lithium in hospitalized aggressive children with conduct disorder: a double-blind and placebo-controlled study. J Am Acad Child Adolesc Psychiatry 1995; 34: 445-53
48. Malone RP, Delaney JF, Carter J, et al. A double-blind placebo-controlled study of lithium in hospitalized aggressive children and adolescents with conduct disorder. Arch Gen Psychiatry 2000; 57: 649-54
49. Steiner H, Peterson ML, Saxena K, et al. Divalproex sodium for the treatment of conduct disorder: a randomized controlled clinical trial. J Clin Psychiatry 2003; 64 (10): 1183-91
50. Cueva JE, Overall JE, Small AM, et al. Carbamazepine in aggressive children with conduct disorder: a double-blind and placebo-controlled study. J Am Acad Child Adolesc Psychiatry 1996; 35 (4): 480-90
51. Armenteros JL, Lewis JE. Citalopram treatment for impulsive aggression in children and adolescents: an open pilot study. J Am Acad Child Adolesc Psychiatry 2002; 41: 522-9
52. Mozes T, Meiri G, Ben-Amity G, et al. Reboxetine as an optional treatment for hyperkinetic conduct disorder: a prospective open-label trial. J Child Adolesc Psychopharmacol 2005 Apr; 15 (2): 259-69
53. Klein RG, Abikoff H, Klass E, et al. Clinical efficacy of methylphenidate in conduct disorder with and without attention hyperactivity deficit hyperactivity disorder. Arch Gen Psychiatry 1997; 54 (12): 1073-80
54. Kolko DJ, Bukstein OG, Barron J. Methylphenidate and behavior modification in children with ADHD and comorbid ODD or CD: main and incremental effects across settings. J Am Acad Child Adolesc Psychiatry 1999; 38: 578-86
55. Hazel PL, Stuart JE. A randomized controlled trial of clonidine added to psychostimulant medication for hyperactive and aggressive children. J Am Acad Child Adolesc Psychiatry 2003; 42 (8): 886-94
56. Kaplan SL, Simms RM, Busner J. Prescribing practices of outpatient child psychiatrists. J Am Acad Child Adolesc Psychiatry 1994; 33: 35-44
57. Pappadopulus E, Macintyre II JC, Crimson ML, et al. Treatment recommendations for the use of antipsychotics for aggressive youth (TRAAY): part II. J Am Acad Child Adolesc Psychiatry 2003; 42: 145-61
58. Greenhill LL, Solomon M, Pleak R, et al. Molindone hydrochloride treatment of hospitalized children with conduct disorder. J Clin Psychiatry 1985; 46 (8): 20-5
59. Campbell M, Small AM, Green WH, et al. Behavioral efficacy of haloperidol and lithium carbonate: a comparison in hospitalized aggressive children with conduct disorder. Arch Gen Psychiatry 1984; 41: 650-6
60. Bassarath L. Medication strategies in childhood aggression: a review. Can J Psychiatry 2003; 48: 367-73
61. Schur SB, Sikich L, Findling RL, et al. Treatment recommendations for the use of antipsychotics for aggressive youth (TRAAY). Part I: a review. J Am Acad Child Adolesc Psychiatry 2003; 42: 132-44
62. Seeman P. Atypical antipsychotics: mechanism of action. Can J Psychiatry 2002; 47: 27-38
63. Kane JM. Extrapyramidal side effects are unacceptable. Eur Neropsychopharmacol 2001; 11 Suppl. 4: S397-403
64. Goldstein JM. The new generation of antipsychotic drugs: how atypical are they? Int J Neuropsychopharmacol 2000; 3: 339-49
65. Meltzer HY, Matsubara S, Lee JC. Classification of typical and atypical antipsychotic drugs on the basis of dopamine D1, D2 and serotonin 2 pKi values. J Pharmacol Exp Ther 1989; 251: 238-46
66. Fisman S, Steele M. Use of risperidone in pervasive developmental disorders: a case series. J Child Adolesc Psychopharmacol 1996; 6 (3): 177-90
67. Findling RL, Maxwell K, Wiznitzer M. An open clinical trial of risperidone monotherapy in young children with autistic disorder. Psychopharmacol Bull 1997; 33 (1): 155-9
68. Horrigan JP, Barnhill LJ. Risperidone and explosive aggressive autism. J Autism Dev Disord 1997 Jun; 27 (3): 313-23
69. McDougle CJ, Holmes JP, Bronson MR, et al. Risperidone treatment of children and adolescents with pervasive developmental disorders: a prospective open-label study. J Am Acad Child Adolesc Psychiatry 1997 May; 36 (5): 685-93
70. Buitelaar JK, Van Der Gaag RJ, Cohen-Kettenis P, et al. A randomized controlled trial of risperidone in the treatment of aggression in hospitalized adolescents with subaverage cognitive abilities. J Clin Psychiatry 2001; 62 (4): 239-48
71. Snyder R, Turgay A, Aman M, et al. Effects of risperidone on conduct and disruptive behavior disorders in children with subaverage IQs. J Am Acad Child Adolesc Psychiatry 2002; 41: 1026-36
72. Findling RL, McNamara NK, Braniky LA, et al. A double-blind pilot study of risperidone in the treatment of conduct disorder. J Am Acad Child Psychiatry 2000; 39 (4): 509-16
73. Van Bellinghen M, De Troch C. Risperidone in the treatment of behavioral disturbances in children and adolescents with borderline intellectual functioning: a double-blind, placebo-controlled pilot trial. J Child Adolesc Psychopharmacol 2001; 11 (1): 5-13
74. Croonenberghs J, Fegert JM, Findling RL, et al. Risperidone in children with disruptive behavior disorders and subaverage intelligence: a 1-year, open-label study of 504 patients. J Am Acad Child Adolesc Psychiatry 2005; 44: 64-72
75. Masi G, Milone A, Canepa G, et al. Olanzapine treatment in adolescents with severe conduct disorder. Eur Psychiatry 2006; 21: 51-7
76. Domon SE, Webber JC. Hyperglycemia and hypertriglyceridemia secondary to olanzapine. J Child Adolesc Psychopharmacology 2001; 11: 285-8
77. Gury C, Canceil O, Iaria P. Antipsychotic drugs and cardiovascular safety: current studies of prolonged QT interval and risk of ventricular arrhythmia. Encephale 2000; 26: 62-72
78. Koller E, Malozowski S, Doraiswamy PM. Atypical antipsychotic drugs and hyperglycemia in adolescents. JAMA 2001; 286: 2547-8
79. Findling RL, McNamara NK, Gracious BL. Paediatric uses of atypical antipsychotics. Expert Opin Pharmacotherapy 2000; 39: 509-16
80. McConville BJ, Sorter MT. Treatment challenges and safety considerations for antipsychotic use in children and adolescents with psychoses. J Clin Psychiatry 2004; 65: 20-9
81. McDougle CJ, Stigler KA, Posey DJ. Treatment of aggression in children and adolescents with autism and conduct disorder. J Clin Psychiatry 2003; 64 Suppl. 4: 16-25
82. Donovan SJ, Susser ES, Nunes EV, et al. Divalproex treatment of disruptive adolescents: a report of 10 cases. J Clin Psychiatry 1997; 58: 12-5
83. Donovan SJ, Stewart JW, Nunes EV, et al. Divalproex treatment for youth with explosive temper and mood lability: a double-blind, placebo-controlled crossover design. Am J Psychiatry 2000; 157: 818-20
84. Dale PG. Lithium therapy in aggressive mentally subnormal patients. Br J Psychiatry 1980; 137: 469-74
85. Delong GR, Aldershof AL. Long-term experience with lithium treatment in childhood: correlation with clinical diagnosis. J Am Acad Child Adolesc Psychiatry 1987; 26: 389-94
86. Rifkin A, Karajgi B, Dicker R, et al. Lithium treatment of conduct disorder in adolescents. Am J Psychiatry 1997; 154 (4): 554-5
87. Kafantaris V, Campbell M, Padron-Gayol MV, et al. Carbamazepine in hospitalized aggressive conduct disorder children: an open pilot study. Psychopharmacol Bull 1992; 28: 193-9
88. Gerardin P, Cohen D, Mazet P, et al. Drug treatment of conduct disorder in young people. Eur Neuropsychopharmacol 2002; 12: 361-70
89. Soller M, Karnik NS, Steiner H. Psychopharmacologic treatment of juvenile offenders. Child Adolesc Psychiatr Clin N Am 2006; 15: 477-99
90. Coccaro EF, Kavoussi RJ, Hauger RL. Serotonin function and antiaggressive response to fluoxetine: a pilot study. Biol Psychiatry 1997; 42: 546-52
91. Cherek DR, Lane SD, Pietras CJ, et al. Effects of chronic paroxetine administration on measures of aggressive and impulsive responses of adult males with a history of conduct disorder. Psychopharmacology (Berl) 2002; 159: 266-74
92. Zubieta JK, Alessi NE. Acute and chronic administration of trazodone in the treatment of disruptive behavior disorders in children. J Clin Psychopharmacol 1992; 12: 346-51
93. Riggs PD, Mikulich SK, Coffman LM, et al. Fluoxetine in drug-dependent delinquents with major depression: an open trial. J Child Adolesc Psychopharmacol 1997; 7 (2): 87-95
94. Riggs PD, Leon SL, Mikulich SK, et al. An open trial of bupropion for ADHD in adolescents with substance use disorders and conduct disorder. J Am Acad Child Adolesc Psychiatry 1998; 37 (12): 1271-8
95. Bond AL. Antidepressant treatments and human aggression. Eur J Pharmacol 2005; 526: 218-25
96. US Food and Drug Administration. Antidepressant use in children, adolescents, and adults [online]. Available from URL: http://www.fda.gov/cder/ drug/antidepressants/default.htm [Accessed 2006 May 31]
97. Eisenberg L, Lachman R, Molling PA, et al. A psychopharmacologic experiment in a training school for delinquent boys. Am J Orthopsychiatry 1963; 33: 431-47
98. Maletzky B. d-Amphetamine and delinquency: hyperkinesis persisting. Dis Nerv Syst 1974; 35: 543-7
99. Kaplan SL, Busner J, Kupietz S, et al. Effects of methylphenidate on adolescents with aggressive conduct disorder and ADDH: a preliminary report. J Am Acad Child Adolesc Psychiatry 1990; 29: 719-23
100. Connor DF, Barkley RA, Davis HT. A pilot study of methylphenidate, clonidine, or the combination of both in ADHD comorbid with aggressive oppositional defiant or conduct disorder. Clin Pediatr (Phila) 2000; 39 (1): 15-25
101. Scholtens J, Roozen M, Mirmiran M, et al. Role of noradrenaline in behavioral changes after defeat in male and female rats. Behav Brain Res 1990; 36: 199-202
102. Foote L, Aston-Jones GS. Pharmacology and physiology of central noradrenergic systems. In: Bloom FF, Kupfer DJ, editors. Psychopharmacology: the fourth generation of progress. New York: Raven Press, 1995: 335-45
103. Kemph JP, DeVane CL, Levin GM, et al. Treatment of aggressive children with clonidine: results of an open pilot study. J Am Acad Child Adolesc Psychiatry 1993; 32: 577-81
104. Henggeler SW, Cunningham PB, Pickrel SG, et al. Multisystemic therapy: an effective violence prevention approach for serious juvenile offenders. J Adolesc 1996; 19: 47-61
105. Fisher PA, Gunnar MR, Chamberlain P, et al. Preventive intervention for maltreated preschool children: impact on children's behavior, neuroendocrine activity, and foster parent functioning. J Am Acad Child Adolesc Psychiatry 2000; 39 (11): 1356-64
106. Borduin CM, Henggeler SW, Blaske DM, et al. Multisystemic treatment of adolescent sexual offenders. Int J Offender Ther Comp Criminol 1990; 34: 105-13
107. Chamberlain P, Reid JB. Comparison of two community alternatives to incarceration for chronic juvenile offenders. J Consult Clin Psychol 1998; 66: 624-33
108. Hill J. Biological, psychological and social processes in the conduct disorders. J Clin Psychol Psychiatry 2002; 43: 133-64
109. Plomin R, Owen MJ, McGuffin P. The genetic basis of complex human behavior. Science 1994; 264: 1733-9
110. Caspi A, McClay J, Moffitt TE, et al. Role of genotype in the cycle of violence in maltreated children. Science 2002; 297: 851-4
111. Barzman DH, McConville BJ, Masterson B, et al. Impulsive aggression with irritability and responsive to divalproex: a pediatric bipolar spectrum disorder phenotype? J Affect Disord 2005; 88: 279-85
112. Biederman J, Faraone SV, Wozniak J, et al. Parsing the association between bipolar, conduct, and substance use disorders: a familial risk analysis. Biol Psychiatry 2000; 48: 1034-44
113. Biederman J, Mick E, Wozniak J, et al. Can a subtype of conduct disorder linked to bipolar disorder be identified? Inteserious gration of findings from the Massachusetts General Hospital Pediatric Psychopharmacology Research Program. Biol Psychiatry 2003; 53: 952-60
114. Clingempeel WG, Henggeler SW. Randomized clinical trials, developmental theory, and antisocial youth: guidelines for research. Dev Psychopathol 2002; 14: 695-711
115. Zito JM, Safer DJ, dosReis S, et al. Psychotropic practice patterns for youth: a 10-year perspective. Arch Pediatr Adolesc Med 2003; 157: 17-25
116. Wiznitzer M, Findling RL. Why do psychiatric drug research in children? Lancet 2003; 361: 1147-8
117. Carrey N. Developmental neurobiology implications for pediatric psychopharmacology. Can J Psychiatry 2001; 46: 810-8
118. Vitiello B. Psychopharmacology for young children: clinical needs and research opportunities. Pediatrics 2001; 108: 983-9